Compugen (Israeli company)
 |
|
| Public | |
| Traded as |
NASDAQ: CGEN : CGEN |
| Industry | Biotechnology |
| Founded | 1993 |
| Founder | Eli Mintz Simchon Faigler Amir Natan |
| Headquarters | Holon, Israel |
|
Key people
|
Martin Gerstel (Chairman) Anat Cohen-Dayag (Pres. & CEO) |
| Revenue |
 US$ 1.1 million (2010)
|
 US$ -7.9 million (2010)
|
|
 US$ -7.2 million (2010)
|
|
| Website | www |
|
Footnotes / references |
|
Compugen (Hebrew: קומפיוג'ן) is a publicly traded drug discovery company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the .
Compugen operates in two areas of the biotechnology industry: it develops and markets bioinformatics software platforms and engages in in silico drug discovery. Over the years it has partnered with companies the likes of Pfizer, Bayer, Novartis, Abbott, BioLineRx, and Seattle Genetics.Roche and Five Prime Therapeutics are among Compugen's competitors.
CGEN-15029 is the lead agent in their immuno-oncology product portfolio.
Compugen was founded in 1993 by Eli Mintz, Simchon Faigler and Amir Natan. Mintz conceived of the idea for the company in 1991 while accompanying his wife, Liat Mintz, to a genomics engagement at the Pasteur Institute in France. She commented that the quantities of data being produced by scientists involved in DNA sequencing exceeded what computers could process at reasonable speeds. Eli Mintz partnered with colleagues Faigler and Natan from the IDF's elite Talpiot program to develop a more powerful computer; and indeed, the company's first computer, dubbed the "Bioccelerator," boasted speeds up to one thousand times faster than other platforms being used at the time. In 1997, the company followed this success by introducing LEADS, an EST clustering and assembly platform. By around 2001, Compugen had effected a shift in its business model from a company whose almost exclusive focus was marketing computer programs and applications to one whose operations extended into the diagnostics and therapeutics fields.
...
Wikipedia